IL243843A0 - Use of an immunoconjugate antibody from itansanoid against 1 muc for the treatment of solid tumors - Google Patents

Use of an immunoconjugate antibody from itansanoid against 1 muc for the treatment of solid tumors

Info

Publication number
IL243843A0
IL243843A0 IL243843A IL24384316A IL243843A0 IL 243843 A0 IL243843 A0 IL 243843A0 IL 243843 A IL243843 A IL 243843A IL 24384316 A IL24384316 A IL 24384316A IL 243843 A0 IL243843 A0 IL 243843A0
Authority
IL
Israel
Prior art keywords
muc1
treatment
solid tumors
maytansinoid immunoconjugate
immunoconjugate antibody
Prior art date
Application number
IL243843A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL243843A0 publication Critical patent/IL243843A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL243843A 2013-08-02 2016-01-31 Use of an immunoconjugate antibody from itansanoid against 1 muc for the treatment of solid tumors IL243843A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306119 2013-08-02
PCT/EP2014/066345 WO2015014879A1 (en) 2013-08-02 2014-07-30 Use of anti-muc1 maytansinoid immunoconjugate antibody for the treatment of solid tumors

Publications (1)

Publication Number Publication Date
IL243843A0 true IL243843A0 (en) 2016-04-21

Family

ID=49036539

Family Applications (1)

Application Number Title Priority Date Filing Date
IL243843A IL243843A0 (en) 2013-08-02 2016-01-31 Use of an immunoconjugate antibody from itansanoid against 1 muc for the treatment of solid tumors

Country Status (12)

Country Link
US (1) US20160347856A1 (enExample)
EP (1) EP3027218A1 (enExample)
JP (1) JP2016525560A (enExample)
KR (1) KR20160035600A (enExample)
CN (1) CN105592861A (enExample)
AU (1) AU2014298514A1 (enExample)
CA (1) CA2919932A1 (enExample)
EA (1) EA201690321A1 (enExample)
IL (1) IL243843A0 (enExample)
MX (1) MX2016001541A (enExample)
TW (1) TW201605479A (enExample)
WO (1) WO2015014879A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109147874A (zh) * 2014-09-02 2019-01-04 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
GB201506388D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W Site-specific antibody-drug conjugates
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
CN105997942B (zh) * 2016-06-24 2019-01-29 浙江大学 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用
EP3570881A4 (en) * 2017-01-18 2020-08-19 Nanocruise Pharmaceutical Ltd. MONOCLONAL AND HUMANIZED ANTIBODIES DIRECTED AGAINST CANCER GLYCOPEPTIDE
EP3665161B1 (en) * 2017-08-09 2023-09-27 Helmholtz-Zentrum für Infektionsforschung GmbH New targeted cytotoxic ratjadone derivatives and conjugates thereof
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
CN113260383A (zh) * 2018-11-02 2021-08-13 西托姆克斯治疗公司 可活化的抗cd166抗体及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1291898A (zh) * 1998-02-25 2001-04-18 若素制药株式会社 用于角膜上皮疾病的药物
AU2004258955C1 (en) * 2003-07-21 2012-07-26 Immunogen, Inc. A CA6 antigen-specific cytotoxic conjugate and methods of using the same
EA020130B9 (ru) * 2005-08-22 2014-10-30 Иммьюноджен, Инк. Специфичное к антигену са6 антитело, содержащий его цитотоксический конъюгат и способы применения конъюгата
WO2010126552A1 (en) * 2009-04-30 2010-11-04 Immunogen, Inc. Potent cell-binding agent drug conjugates
CN102596922A (zh) * 2009-10-06 2012-07-18 免疫基因公司 有效的缀合物和亲水性连接体

Also Published As

Publication number Publication date
WO2015014879A1 (en) 2015-02-05
AU2014298514A1 (en) 2016-03-10
WO2015014879A9 (en) 2015-11-19
JP2016525560A (ja) 2016-08-25
CN105592861A (zh) 2016-05-18
CA2919932A1 (en) 2015-02-05
KR20160035600A (ko) 2016-03-31
MX2016001541A (es) 2016-08-18
EA201690321A1 (ru) 2016-12-30
EP3027218A1 (en) 2016-06-08
TW201605479A (zh) 2016-02-16
US20160347856A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
IL313188B2 (en) Anti-B7-H1 antibodies for tumor treatment
IL273090B (en) Methods and preparations for the treatment of cancer
EP3027192A4 (en) Methods for the treatment of solid tumors
IL243843A0 (en) Use of an immunoconjugate antibody from itansanoid against 1 muc for the treatment of solid tumors
IL243430A0 (en) Methods and kits for molecular classification of tumors
IL244884A0 (en) Antibodies conjugated against ly75 for cancer therapy
IL250507A0 (en) Anti-ck8 antibodies for use in cancer therapy
IL245551A0 (en) Anti-matriptase antibodies for cancer treatment
PT2984108T (pt) Anticorpos anti-s100a7 para o tratamento e diagnóstico de cancro
EP3030268A4 (en) Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers
EP2991650A4 (en) Methods for the treatment of cancer
PL2959021T3 (pl) Sposoby i zestawy do podtypowania molekularnego guzów
IL255273B (en) igf-1r antibody and its use for cancer diagnosis
IL255272A0 (en) igf-1r antibody and its use for cancer diagnosis
EP3016948B8 (en) 2-acylaminothiazoles for the treatment of cancer
HK1226755A1 (en) Antibodies anti matriptase for the treatment of cancer